Curapath, (formerly PTS) a leader in the custom design, development, and end-to-end GMP manufacture of polymer and lipid-based drug delivery systems is partnering with the organizers of the LNP Development Europe Summit. Dr. Vincent Nebot, CTO of Curapath, will be delivering a talk entitled “Development of Shielding Lipid Novel Excipients for LNP formulations”. This summit is the only European conference solely dedicated to LNP formulation and process development to enable seamless scale-up, while keeping GMP compliance and manufacturing in mind.
Given the rapid developments in the field and the success of Pfizer / BioNTech’s mRNA vaccine, lipid nanoparticles have finally reached an inflection point. With new technologies and advancements, LNPs are now a commercially viable delivery vehicle with clinical utility. We have only scratched the surface of the applications of lipid nanocarriers. The past 24 months saw a wave of innovations to exploit the use of LNP beyond mRNA vaccines.
Within Europe in 2022, we have witnessed huge investments to establish LNP Centres of Excellence, LNP GMP production facilities in Germany, UK, Spain and funded projects by the European Commission in Belgium.
Emulating the success of our US Summit, this European agenda will bring together experts across CSL Behring, Janssen, AstraZeneca, CPI, Insmed and more. The LNP Development Summit aims to bring the formulation and process development experts within the LNP community together to exploit future potential.
